Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.

Nicola PersoneniMarina BarettiSilvia BozzarelliPaola SpaggiariLuca RubinoMaria Chiara TronconiUberto Fumagalli RomarioRiccardo RosatiLaura GiordanoMassimo RoncalliArmando SantoroLorenza Rimassa

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2016)

HER2 status is an independent prognostic biomarker in gastroesophageal adenocarcinomas receiving epirubicin-based chemotherapy. Compared to diagnostic biopsies, HER2 assessment in multiple resection specimens might lower the risk of sampling errors. These findings have several implications with respect to the optimal choice of the sample to be submitted to IHC testing of HER2.

Keyphrases

locally advanced
squamous cell carcinoma
single cell
rectal cancer
emergency department
patient safety
radiation therapy
adverse drug
ultrasound guided